At the same time, Ostro launched a new website and brand identity, grew annual revenue by over 250%, increased the employee base by 50%, and closed an additional $45 million in funding from Founders Fund, Byers Capital, Caffeinated Capital, Greycroft, Bling Capital, Trust Ventures, and RRE Ventures, bringing total funding to over $55M.

Technology partnership aims to increase engagement by educating consumers about CooperSurgical's ParagardTRUMBULL, Conn., Dec. 14, 2022 /PRNewswire/ -- CooperSurgical, Inc., a leader in women's healthcare, and Ostro , a leading engagement platform dedicated to educating and empowering consumers and healthcare providers, today announced their partnership to launch a new consumer engagement solution for CooperSurgical's hormone-free IUD, Paragard. Paragard is an FDA-approved intrauterine device that prevents pregnancy for up to 10 years."By partnering with Ostro, we are truly accelerating what's possible." - Holly Sheffield, President, CooperSurgical Tweet this CooperSurgical logo"CooperSurgical is dedicated to putting time on the side of women, babies, and families at the moments that matter the most in life. Patient education along with access to care is at the forefront of our mission," said Holly Sheffield, President, CooperSurgical. "By partnering with Ostro, we are truly accelerating what's possible. We are empowering women to take control of their future."With the implementation of the Ostro technology, Paragard will now offer consumers a more personalized experience on Paragard.com that includes the option of connecting with a live Nurse Navigator who can answer questions and assist patients in determining if Paragard may be right for them

MIAMI, FL, RxDefine, a healthcare engagement platform changed its name to Ostro and raised an additional $45 million in funding.